Captor Therapeutics Spolka Akcyjna EBIT

Captor Therapeutics Spolka Akcyjna's ebit stands at $-50M as of June 2026. That compares with $-39M in the prior-year period — down 26.8% year over year. That is below the Healthcare sector average of $110B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Captor Therapeutics Spolka Akcyjna reported $-50M in EBIT versus $-39M a year earlier — a 26.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Captor Therapeutics Spolka Akcyjna sits lower the Healthcare benchmark ($110B) with a EBIT of $-50M. That is roughly 100.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-39M in the prior-year period — down 26.8% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Captor Therapeutics Spolka Akcyjna's EBIT evolved across reporting periods, while the comparison chart places CTX.WA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.